2016
DOI: 10.1016/j.colsurfb.2016.08.052
|View full text |Cite
|
Sign up to set email alerts
|

Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
59
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 149 publications
(62 citation statements)
references
References 64 publications
0
59
0
1
Order By: Relevance
“…3 PLGA nanoparticles can be modi-ed, for example with contrast agents and drugs, by either covalent coupling or non-covalent loading using the hydrophobic effect. [4][5][6] PLGA protects the drug from fast degradation and the release time of the encapsulated cargo from the particles can be modulated by altering the synthesis parameters and polymer composition. 7 Loading the particles with liquid peruorocarbons (PFCs) for uorine ( 19 F) MRI is advantageous for biomedical use, as it can be used for in vivo non-invasive imaging.…”
Section: Introductionmentioning
confidence: 99%
“…3 PLGA nanoparticles can be modi-ed, for example with contrast agents and drugs, by either covalent coupling or non-covalent loading using the hydrophobic effect. [4][5][6] PLGA protects the drug from fast degradation and the release time of the encapsulated cargo from the particles can be modulated by altering the synthesis parameters and polymer composition. 7 Loading the particles with liquid peruorocarbons (PFCs) for uorine ( 19 F) MRI is advantageous for biomedical use, as it can be used for in vivo non-invasive imaging.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, systemic toxicity of PLGA@QT NPs (20 mg/kg, i.v.) was not observed in the histological study of mouse tissues 5, 15, or 30 days after injection (Sun et al., ).…”
Section: Quercetin and Memorymentioning
confidence: 91%
“…However, an important aspect to consider, besides proving a therapeutic concept in animal models and generating a drug to effectively translate that concept to clinics, is the challenge to efficaciously deliver a molecule to the brain due to constraints of bioavailability and the blood-brain barrier. In that regard, nanoparticle-based drug engineering (234) and/or MSC-based therapy (200), if proved efficient, could help overcome a rampant problem encountered in the pharmaceutical industry in general and lead to clinical trials with more positive outcomes. Hence, XBP1 and downstream pathways (see Figure 1) merit aggressive and thorough exploration as genuine therapeutic targets that could pave the way for more effective disease-modifying therapies in AD pathology.…”
Section: Resultsmentioning
confidence: 99%